Waters Introduces Next-Generation Alliance iS HPLC System Aimed at Reducing Up to 40% of Common Lab Errors
20.3.2023 15:00:00 EET | Business Wire | Press release
PITTCON 2023 – Waters Corporation (NYSE:WAT) today introduced Alliance iS, the next-generation intelligent HPLC System, designed to reduce compliance risk by adding new levels of proactive error detection, troubleshooting and ease-of-use. When combined with Waters’ compliance-ready Empower Chromatography Software and eConnect™ HPLC Columns, the Alliance iS High Performance Liquid Chromatography (HPLC) System streamlines the task of making accurate and precise measurements by detecting and eliminating common errors by up to 40%.i In doing so, the Alliance iS HPLC System helps QC laboratories consistently meet quality, safety, compliance, and on-time product delivery goals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230320005167/en/
The new Waters Alliance iS HPLC System is an intuitively simple, rugged, and reliable high performance liquid chromatograph designed specifically for the pharmaceutical quality control (QC) laboratory. The instrument makes QC laboratories more efficient by reducing common errors that cause up to 40% of failed sample sets and subsequent out-of-specification results, re-tests and investigations. (Photo: Business Wire)
“Today’s QC laboratories are very different than they were 50 years ago when Waters introduced its first commercial HPLC system helping ensure the tens of thousands of prescription drugs on the market are pure, safe, and will work as expected,” said Udit Batra, President & CEO, Waters Corporation. “Our conversations with hundreds of QC managers and bench analysts have yielded a deeper understanding of what they need today from a state-of-the-art HPLC system to help them perform at their best. The Waters Alliance iS HPLC System is ideally suited to address issues such as staff training, error-reduction, risk management, and compliance, helping bring significant productivity and quality improvements to high-volume QC laboratories.”
Based on broad and in-depth customer insights, the Alliance iS HPLC System is thoughtfully designed for the unique needs of the QC laboratory, bringing intuitive simplicity to routine measurements. With visual prompts and alerts delivered via an intuitive touchscreen interface, the system notifies the operator if an improper method is chosen for an application, when a sample vial is missing, when it’s time to refill a solvent bottle, or if it’s time for system maintenance. These are common conditions that when caught early enough, can eliminate system errors that would otherwise degrade the ability of scientists to get needed drugs to patients and ultimately cost a laboratory time and money.
The system also integrates with the cloud-native waters_connect™ System Monitoring Software enabling real-time monitoring of the Alliance iS HPLC System and any other chromatography instruments controlled by Empower Software. Laboratory managers can view the live status of their HPLC instrument fleet from anywhere and at any time to further improve equipment utilization and overall productivity.ii
Waters Alliance iS HPLC System feature highlights include:
- The very latest compliance-ready, industry-standard Empower Chromatography Software with full audit tracking capabilities.
- Advanced instrument touchscreen for guided system operation and maintenance.
- eConnect Column Tag Technology to link column information including injection counts via near-field communication (NFC) technology.
- Automated system diagnostic pre-checks to help meet error reduction key performance indicators (KPIs).
- Tool-free fittings to prevent leaks and provide better chromatography.
The Waters Alliance iS HPLC System will be available starting in May 2023.
Additional Resources
- Learn more about Waters Alliance iS HPLC System product features and benefits
- Download the Alliance iS HPLC System brochure
- Read the blog post Waters Pushes the Boundaries with Intuitive Simplicity
- Visit the Waters online press kit for Alliance iS and PittCon ’23 news
- Follow and connect with Waters via LinkedIn, Twitter, and Facebook
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for more than 60 years. With more than 8,200 employees worldwide, Waters operates directly in more than 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.
Waters, Alliance, eConnect, waters_connect, and Empower are trademarks of Waters Corporation.
i *Estimate based on Waters' market research in 2022 after surveying 56 global pharmaceutical company QC labs.
ii The waters_connect System Monitoring application is only available in Europe and North America at this time.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230320005167/en/
Contact information
Brian J. Murphy
PR Manager, Corporate Communications
Waters Corporation
brian_j_murphy@waters.com
+1 508-482-2614
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Teledyne FLIR Defense Wins $17.5 Million Contract from armasuisse to Deliver Black Hornet 4 Nano-Drones for Dismounted and Vehicle-Integrated Reconnaissance2.2.2026 09:00:00 EET | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE:TDY), announced that it has received a $17.5 million contract from armasuisse, the Swiss Federal Office of Defence Procurement, to deliver a large number of Black Hornet® 4 Personal Reconnaissance Systems, one of the world’s most advanced and widely deployed nano-drones. Black Hornet 4 was selected as an airborne dismountable Intelligence, Surveillance, and Reconnaissance (ISR) capability sensor for armasuisse’s Piranha 8x8 Armored engineering vehicle program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260201061637/en/ Teledyne FLIR Defense has won a $17.5 million contract from armasuisse, the Swiss Federal Office of Defence Procurement, to deliver a large number of Black Hornet® 4 Personal Reconnaissance Systems, one of the world’s most advanced and widely deployed nano-drones. Black Hornet 4 was selected as an airborne capability sensor for armasui
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation aesthetic solutions that address evolving needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260201157212/en/ “We pioneered the development of RelabotulinumtoxinA to address the growing demand for faster-acting and longer-lasting anti-wrinkle solutions. We’re excited about the potential to bring this innovative neuromodulator to the U.S., offering advanced performance and ease of use and building on our portfolio of neuromodulators that meets the full spectrum of injecto
High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 09:00:00 EET | Press release
Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 19:27:00 EET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom